Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of (90) Y-DOTA-D-Phe1-Tyr3 octreotide.

Savelli, G; Bertagna, Francesco; Franco, F; Dognini, L; Bosio, G; Migliorati, E; Rodella, C; Biasiotto, Giorgio; Bettinsoli, G; Minari, C; Zaniboni, A; Ferrari, C; Tomassetti, P; Ferrari, V; Giubbini, Raffaele